Regen BioPharma Inc Contracts & Agreements

Purchase Agreement (Filed With SEC on September 13, 2024)

Cover Page Interactive Data File (embedded within the Inline XBRL document) (Filed With SEC on September 13, 2024)

NOTE PAYABLE ZANDER $15,000 (Filed With SEC on August 13, 2024)

NOTE PAYABLE ZANDER $25,000 (Filed With SEC on August 13, 2024)

Agreement with Value Quest Inc (Filed With SEC on April 29, 2024)

Amendment to Sublease (Filed With SEC on April 29, 2024)

Sublease Agreement (Filed With SEC on April 29, 2024)

License Agreement Regen Zander (Filed With SEC on September 25, 2023)

Assignment License Agreement Regen Zander (Filed With SEC on September 25, 2023)

License Agreement Oncology Pharma Regen (Filed With SEC on September 25, 2023)

License Agreement Oncology Pharma KCL (Filed With SEC on September 25, 2023)

Convertible Note 1 (Filed With SEC on September 25, 2023)

Convertible Note 2 (Filed With SEC on September 25, 2023)

Convertible Note 3 (Filed With SEC on September 25, 2023)

Convertible Note 4 (Filed With SEC on September 25, 2023)

Convertible Note Zander Therapeutics, Inc (Filed With SEC on September 25, 2023)

Convertible Note 5 (Filed With SEC on September 25, 2023)

Transfer Agent Letter (Filed With SEC on September 25, 2023)

Purchase Agreement (Filed With SEC on September 18, 2023)

Equity Line Agreement (Filed With SEC on September 18, 2023)

Registration Rights Agreement (Filed With SEC on September 18, 2023)

Convertible Note 5 (Filed With SEC on April 13, 2023)

Convertible Note Zander Therapeutics, Inc (Filed With SEC on April 13, 2023)

Convertible Note 4 (Filed With SEC on April 13, 2023)

Convertible Note 3 (Filed With SEC on April 13, 2023)

Convertible Note 2 (Filed With SEC on April 13, 2023)

Convertible Note 1 (Filed With SEC on April 13, 2023)

License Agreement Oncology Pharma KCL (Filed With SEC on April 13, 2023)

License Agreement Oncology Pharma Regen (Filed With SEC on April 13, 2023)

Assignment License Agreement Regen Zander (Filed With SEC on April 13, 2023)

License Agreement Regen Zander (Filed With SEC on April 13, 2023)

Hais Agreement (Filed With SEC on January 19, 2023)

Reddy Agreement (Filed With SEC on January 19, 2023)

Dawald Agreement (Filed With SEC on January 19, 2023)

Sublease Agreement (Filed With SEC on January 14, 2022)

BIOTECH ResearchGroup SCOPEOF WORK ( SOW) ORDER (Filed With SEC on October 19, 2021)

Promissory Note (Filed With SEC on September 24, 2021)

Settlement and Release Agreement (Filed With SEC on September 24, 2021)

SETTLEMENT AGREEMENT (Filed With SEC on September 16, 2021)

REGEN BIOPHARMA, INC (Filed With SEC on April 16, 2021)

Regen Agreement (Filed With SEC on April 8, 2021)

KCL Agreement (Filed With SEC on April 8, 2021)

AGREEMENTBY AND BETWEEN REGEN BIOPHARMA, INC. AND TODD S. CAVEN (Filed With SEC on March 25, 2021)

Form of Convertible Note 50,000 (Filed With SEC on August 29, 2019)

Form of Convertible Note $100,000 (Filed With SEC on August 29, 2019)

Form of Convertible Note $14,819 (Filed With SEC on August 29, 2019)

Form of Convertible Note $20,331 (Filed With SEC on August 29, 2019)

Form of Amendment Convertible Note (Filed With SEC on August 29, 2019)

Form of Convertible Note $63,000 (Filed With SEC on February 12, 2019)

Form of Convertible Note $75,000 (Filed With SEC on February 12, 2019)

Form of Note Receivable $63,000 (Filed With SEC on February 12, 2019)

Form of Convertible Note $50,000 (Filed With SEC on February 12, 2019)

Form of Note Receivable $50,000 (Filed With SEC on February 12, 2019)

AGREEMENT BY AND BETWEEN KCL THERAPEUTICS, INC. AND HARRY LANDER (Filed With SEC on January 25, 2019)

LICENSEASSIGNMENT AND CONSENT AGREEMENT (Filed With SEC on December 27, 2018)

STOCKPURCHASEAGREEMENT (Filed With SEC on November 20, 2018)

SUBLEASEAGREEMENT (Filed With SEC on November 20, 2018)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on October 4, 2018)

Form of Convertible Note $114,000 (Filed With SEC on August 6, 2018)

Form of Convertible Note $11,500 (Filed With SEC on August 6, 2018)

Form of Convertible Note $25,000 (Filed With SEC on May 14, 2018)

Form of Convertible Note $30,000 (Filed With SEC on May 14, 2018)

Form of Convertible Note $70,000 (Filed With SEC on May 14, 2018)

Convertible Note $115,000 (Filed With SEC on May 14, 2018)

Unit Purchase Agreement $50,000 (Filed With SEC on May 14, 2018)

Agreement with Harry Lander (Filed With SEC on May 14, 2018)

February 7, 2018 Letter Agreement with Zander Therapeutics (Filed With SEC on May 14, 2018)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on February 6, 2018)

AGREEMENT BY AND BETWEEN REGENBIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC. Dated December 15, 2017 (Filed With SEC on January 5, 2018)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on January 5, 2018)

GSCAPITAL PARTNERS, LLC COLLATERALIZEDSECURED PROMISSORY NOTE BACKEND NOTE (Filed With SEC on January 5, 2018)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on January 5, 2018)

GSCAPITAL PARTNERS, LLC COLLATERALIZEDSECURED PROMISSORY NOTE BACKEND NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUEJUNE 16, 2018 (Filed With SEC on January 5, 2018)

LGCAPITAL FUNDING, LLC COLLATERALIZEDSECURED PROMISSORY NOTE BACKEND NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUEAUGUST 23, 2018 (Filed With SEC on January 5, 2018)

BACKEND NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUEAUGUST 23, 2018 BACKEND (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUESEPTEMBER 7, 2018 (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUE SEPTEMBER 7, 2018 BACKEND NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUESEPTEMBER 7, 2018 (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUESEPTEMBER 7, 2018 BACKEND NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. (Filed With SEC on January 5, 2018)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUE DECEMBER 6, 2018 (Filed With SEC on January 5, 2018)

REGENBIOPHARMA, INC. 8%CONVERTIBLE REDEEMABLE NOTE DUE DECEMBER 6, 2018 BACKEND (Filed With SEC on January 5, 2018)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on August 7, 2017)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on May 5, 2017)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on May 5, 2017)

InvestorRelations Consulting Agreement Between RegenBiopharma Inc. And Synergy Business Consultants LLC (Filed With SEC on May 5, 2017)

LICENSEAGREEMENT (Filed With SEC on February 9, 2017)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on January 27, 2017)

CONVERTIBLE PROMISSORY NOTE (Filed With SEC on December 21, 2016)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on August 1, 2016)

INDEMNIFICATIONAGREEMENT (Filed With SEC on July 7, 2016)

ENGAGEMENTAGREEMENT (Filed With SEC on June 8, 2016)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on April 29, 2016)

RESEARCHCOLLABORATION AGREEMENT (Filed With SEC on December 17, 2015)

UNITPURCHASE AGREEMENT REGENBIOPHARMA, INC. (Filed With SEC on November 24, 2015)

AGREEMENTBY AND BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIM (Filed With SEC on November 5, 2015)

EMPLOYMENTAGREEMENT BETWEEN REGENBIOPHARMA, INC. AND HarryM. Lander, Ph.D., M.B.A. (Filed With SEC on October 13, 2015)

AMENDMENTTO LICENSE AGREEMENT DATED APRIL 6, 2015 (Filed With SEC on August 26, 2015)

AGREEMENTBY AND BETWEEN REGEN BIOPHARMA, INC. AND ZANDER THERAPEUTICS, INC. (Filed With SEC on June 26, 2015)

AGREEMENTBY AND BETWEEN REGEN BIOPHARMA, INC. AND SANTOSH KESARI (Filed With SEC on June 15, 2015)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on May 7, 2015)

ConsultingAgreement (Filed With SEC on March 30, 2015)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on March 25, 2015)

AppendixA DESIGNATEDLEASED SPACE - FLOOR PLAN (Filed With SEC on March 25, 2015)

RESEARCHAGREEMENT (Filed With SEC on March 25, 2015)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on March 10, 2015)

PATENTPURCHASE AGREEMENT (Filed With SEC on March 10, 2015)

EMPLOYMENTAGREEMENT BETWEEN REGENBIOPHARMA, INC. AND TODDS. CAVEN (Filed With SEC on February 13, 2015)

EMPLOYMENTAGREEMENT BETWEEN REGENBIOPHARMA, INC. AND DavidR. Koos (Filed With SEC on February 13, 2015)

CONVERTIBLEPROMISSORY NOTE (Filed With SEC on February 9, 2015)

EMPLOYMENTAGREEMENT BETWEEN REGEN BIOPHARMA, INC. AND THOMAS ICHIM (Filed With SEC on January 22, 2015)

EMPLOYMENTAGREEMENT BETWEEN REGEN BIOPHARMA, INC AND CHRISTINE ICHIM (Filed With SEC on January 22, 2015)

AMENDMENTTO SUBLEASE AGREEMENT (AGREEMENT) ENTERED INTO OCTOBER 1, 2014 BY AND BETWEEN ENTEST BIOMEDICAL, INC. ( SUBLESSOR)AND REGEN BIOPHARMA,INC (SUBTENANT) (Filed With SEC on January 22, 2015)

SUBLEASEAGREEMENT (Filed With SEC on December 18, 2014)

ASSIGNMENTOF INVENTION AND PATENT APPLICATION (Filed With SEC on December 18, 2014)

ASSIGNMENTOF INVENTION AND PATENT APPLICATION (Filed With SEC on November 25, 2014)

ConsultingAgreement (Filed With SEC on November 25, 2014)

PROMISSORYNOTE PAYABLE (Filed With SEC on August 7, 2014)

ExclusiveLicense Agreement BetweenOHSU and Regen BioPharma, INC ForInvention Disclosure 0472 (Filed With SEC on October 15, 2013)

EMPLOYMENTAGREEMENT BETWEEN BIO-MATRIXSIENTIFIC GROUP, INC. AND J.CHRISTOPHER MIZER (Filed With SEC on October 15, 2013)

EMPLOYMENTAGREEMENT BETWEEN BIO-MATRIXSCIENTIFIC GROUP, INC. AND THOMASICHIM (Filed With SEC on October 15, 2013)

Regen BioPharma Inc. Awholly owned subsidiary of Bio-Matrix Scientific Group Inc. (Filed With SEC on October 15, 2013)

ExclusiveOption to Negotiate an Exclusive License Between OregonHealth & Science University and RegenBioPharma, Inc. (Filed With SEC on October 15, 2013)

REGENBIO PHARMA INC. Awholly owned subsidiary of Bio matrix Scientific Group, Inc. (Filed With SEC on October 15, 2013)

LICENSE AGREEMENT- EXECUTION (Filed With SEC on October 15, 2013)

SERVICEAGREEMENT (Filed With SEC on October 15, 2013)

Category

Industry

Companies

Contracts

Regen BioPharma Inc Contracts & Agreements